Jefferies Financial Group Initiates Coverage on Aligos Therapeutics (NASDAQ:ALGS)

Analysts at Jefferies Financial Group initiated coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm set a “buy” rating and a $48.00 price target on the stock.

A number of other equities research analysts have also recently commented on ALGS. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Aligos Therapeutics in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Wednesday, January 21st. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, UBS Group initiated coverage on Aligos Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $20.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $6.81 on Thursday. Aligos Therapeutics has a 12-month low of $3.76 and a 12-month high of $13.69. The company has a market capitalization of $42.15 million, a PE ratio of -0.79 and a beta of 2.67. The firm’s 50-day moving average is $7.48 and its two-hundred day moving average is $8.87.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating the consensus estimate of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. On average, analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALGS. Rockefeller Capital Management L.P. lifted its stake in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after purchasing an additional 9,000 shares during the period. XTX Topco Ltd acquired a new stake in shares of Aligos Therapeutics during the fourth quarter worth $215,000. SummitTX Capital L.P. purchased a new stake in shares of Aligos Therapeutics in the fourth quarter valued at $1,299,000. Verition Fund Management LLC purchased a new stake in shares of Aligos Therapeutics in the fourth quarter valued at $664,000. Finally, Marshall Wace LLP acquired a new position in Aligos Therapeutics in the fourth quarter valued at $2,504,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.